Feeding Regulation in SCI
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05406739 |
Recruitment Status :
Recruiting
First Posted : June 6, 2022
Last Update Posted : January 9, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Spinal Cord Injuries | Other: Test Meals | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 32 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Physiological and Behavioral Regulation of Feeding After Spinal Cord Injury |
Actual Study Start Date : | January 5, 2023 |
Estimated Primary Completion Date : | August 21, 2024 |
Estimated Study Completion Date : | August 21, 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: Spinal Cord Injury Group
Participants who have a spinal cord injury will receive two meals on two separate visits between five to seven days.
|
Other: Test Meals
For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute [60 kcal]; 2 slices of bread [120 kcal] with 30 g strawberry jam [75 kcal]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water. After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute [120 kcal]; 4 slices of bread [240 kcal] with 60 g strawberry jam [150 kcal]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water. |
Active Comparator: Control Group
Participants without a spinal cord injury will receive two meals on two separate visits between five to seven days.
|
Other: Test Meals
For the first meal, Participants will be fasted for 8 hours and will consume a test meal of 255 calories (120 g egg substitute [60 kcal]; 2 slices of bread [120 kcal] with 30 g strawberry jam [75 kcal]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 120 mL of water. After five to seven days, participants will be fasted for 10 hours and will consume a second test meal of 510 calories (240 g egg substitute [120 kcal]; 4 slices of bread [240 kcal] with 60 g strawberry jam [150 kcal]; 72% carbohydrate, 24% protein, 2% fat, and 2% fiber) with 240 mL of water. |
- Gastric emptying time [ Time Frame: Up to seven days ]Gastric emptying will be measured by the SmartPill Wireless Motility Capsule
- Upper gastrointestinal transit time [ Time Frame: Up to seven days ]Upper gastrointestinal transit time will be measured by the SmartPill Wireless Motility Capsule
- Change in postprandial ghrelin [ Time Frame: Before the second test meal (up to 7 days) and up to 120 minutes after the second test meal (up to 7 days). ]Measured by serum blood samples
- Change in postprandial peptide tyrosine tyrosine (PYY) [ Time Frame: Before the second test meal (up to 7 days) and up to 120 minutes after the second test meal (up to 7 days). ]Measured by serum blood samples
- Change in postprandial cholecystokinin (CKK) [ Time Frame: Before the second test meal (up to 7 days) and up to 120 minutes after the second test meal (up to 7 days). ]Measured by serum blood samples
- Change in postprandial Glucagon Peptide 1 (GLP-1) [ Time Frame: Before the second test meal (up to 7 days) and up to 120 minutes after the second test meal (up to 7 days). ]Measured by serum blood samples
- Change in subjective appetite rating as measured by Palatability Series Visual Analogue Scale [ Time Frame: Baseline and up to 7 days ]Change in subjective appetite rating will be measured by Palatability Series Visual Analogue Scale that ranges from 0 mm as "not pleasant" to 100 mm as "extremely pleasant"
- Change in subjective appetite rating as measured by Hunger Series Visual Analogue Scale [ Time Frame: Baseline and up to 7 days ]Change in subjective appetite rating will be measured by Hunger Series Visual Analogue Scale that ranges from 0 mm as "not at all hungry" to 100 mm as "totally/a lot/very hungry".
- Total percentage body fat [ Time Frame: Baseline ]Measured by Dual x-ray absorptiometry (DXA)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Spinal Cord Injury (SCI) Participants:
- Adults (≥ 18 years) with tetraplegia (C5-C8) or paraplegia (T1-L2) SCI
- Chronic SCI, denoted as ≥ 12 months post-injury
- American Spinal Injury Association Impairment Scale164 A, B, and C
- Persons with tetraplegia self-report they are able to feed themselves
- Self-report on a bowel care program every-other-day
- English speaking
Control Group (Healthy) Participants:
- Adults (≥ 18 years) without a SCI (will be sex- and age-matched to persons with SCI)
- English speaking
Exclusion Criteria:
For All Participants:
- Currently on a weight loss program/diet and/or actively trying to lose weight
-
Have a self-reported history of
- Diabetes
- Thyroid disease
- Gastrointestinal disease
- Previous abdominal surgery ≤ 3 months prior to the study
- Peripheral nervous system prosthesis
- Swallowing disorders
- Self-reported food allergies to or dislike the test meals.
- Self-reported use of a prokinetic agent, antipsychotic agent, or Glucagon like Peptide 1 (GLP-1) agonists
- Individuals who are not yet adults (infants, children, teenagers)
- Women that self-report they are pregnant or likely to become pregnant
- Prisoners

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05406739
Contact: Gary J Farkas, PhD | 3052434518 | gjf50@med.miami.edu | |
Contact: Dinorah Rodriguez, BSN | 3052432797 | dinorah@med.miami.edu |
United States, Florida | |
University of Miami | Recruiting |
Miami, Florida, United States, 33136 | |
Contact: Gary J Farkas, PhD 305-243-4518 gjf50@med.miami.edu | |
Sub-Investigator: Mark S Nash, PhD |
Principal Investigator: | Gary J Farkas, PhD | University of Miami |
Other Publications:
Responsible Party: | Gary Farkas, Postdoctoral Associate, University of Miami |
ClinicalTrials.gov Identifier: | NCT05406739 |
Other Study ID Numbers: |
20220407 |
First Posted: | June 6, 2022 Key Record Dates |
Last Update Posted: | January 9, 2023 |
Last Verified: | January 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
gut eating appetite hormone |
Spinal Cord Injuries Spinal Cord Diseases Central Nervous System Diseases |
Nervous System Diseases Trauma, Nervous System Wounds and Injuries |